The basic figures of the Dax group are solid. Nevertheless, questions remain.
(Photo: mauritius images)
Dusseldorf Bayer shareholders, who quickly expect the big hit after the change at the top of the board, are likely to be disappointed. Under future boss Bill Anderson, there will be no rapid splitting up of the conglomerate of agricultural and medical businesses, as has been repeatedly demanded in the past.
The 56-year-old, who will take the lead in June, left no doubts about that during his first public appearance recently. Concrete concepts for spin-offs, split-ups or major takeovers? According to the American pharmaceutical manager, such a thing is not his primary approach to what needs to be done.
According to his own statements, the scientist approaches the job with an open mind. But above all he wants to score points with successful products and modernize the organization. According to company circles, Anderson’s job is to bring Bayer forward in the existing structure over the next two to three years.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further
Read on now
Get access to this and every other article in the
web and in our app.
Further